Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Other Investors | Alive

About Recodgen

Recodgen is developing therapeutics targeting genetic expressions to disease

Recodgen Headquarters Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • What is Recodgen's latest funding round?

    Recodgen's latest funding round is Other Investors.

  • Who are the investors of Recodgen?

    Investors of Recodgen include ARCH Venture Partners.

  • Who are Recodgen's competitors?

    Competitors of Recodgen include CoImmune, Selexys Pharmaceuticals, Sorbent Therapeutics, Altheus Therapeutics, Marval Biosciences and 10 more.

You May Also Like

F
Femta Pharmaceuticals

Femta is developing a new generation of antibody therapeutics for major disease indications.

E
Evogenix

Evogenix aims to provide advanced technologies to provide powerful new antibody therapeutics for world markets.

AdAlta Logo
AdAlta

Which is using a platform-technology approach to develop antibody and peptide-based therapeutics against select targets.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

A
Alvine Pharmaceuticals

Alvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 targets gluten and degrades it into small fragments, which, in vitro, diminishes its immunogenicity. ALV003 is being developed as a potential treatment for celiac disease patients in conjunction with a gluten-free diet and is currently in phase 2 clinical development.

R
Ribozyme Pharmaceuticals

Ribozyme Pharmaceuticals offers RNA-based pharmaceuticals for human disease

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.